Last reviewed · How we verify
TAK-816+ DPT-TAKEDA
TAK-816 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
TAK-816 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | TAK-816+ DPT-TAKEDA |
|---|---|
| Also known as | Vaxem Hib |
| Sponsor | Takeda |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This results in decreased glucose levels in the blood, which can help to improve glycemic control in patients with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study of TAK-816 in Healthy Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |